# Garuda Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/garuda-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.garudatx.com
- Total disclosed funding: $158M
- Latest round: Series A (Oct 17, 2024)
- Investors on record: 11

## About

Established in 2021 and based in Massachusetts, US, Garuda Therapeutics, Inc. operates as a biopharmaceutical company that creates hematopoietic stem cell therapies. The company was cofounded by Dr. Dhvanit Shah, Dr. David Scadden, and Dr. Sean Morrison. In March 2025, Garuda Therapeutics, Inc. raised USD 50 million in series A funding from new investor Kyowa Kirin. Returning investors OrbiMed Advisors, Northpond Ventures, Cormorant Asset Management, and other unspecified investors also participated in the round. Garuda is developing a hematopoietic stem cell platform that has the potential to cure more than 70 diseases and eliminate dependency on donor or patient cells. The company's platform technology for generating self-renewing blood stem cells is poised to provide patients with broad access to HLA-compatible transgene-free blood stem cell therapies. The company will use the March 2025 funding to support the expansion of its products.

## Funding rounds

- Series A, Oct 17, 2024, $48M — OrbiMed Advisors, Cormorant Asset Management, Northpond Ventures, Kyowa Kirin
- Series B, Jan 23, 2023, $62M — OrbiMed Advisors, Alexandria Venture Investments, Aisling Capital, Mass General Brigham Ventures, Sectoral Asset Management, Cormorant Asset Management, Northpond Ventures
- Series A, Sep 9, 2021, $48M — OrbiMed Advisors, Aisling Capital, Mass General Brigham Ventures, Sectoral Asset Management, National Resilience, LLC., Cormorant Asset Management, Monashee Investment Management, Ridgeback Asset Management, Northpond Ventures

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series A, Series B
- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Series A, Series B
- Sectoral Asset Management (https://capitalatlas.ai/funds/sectoral-asset-management) — Series A, Series B
- National Resilience, LLC. — Series A
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A, Series B
- Monashee Investment Management — Series A
- Ridgeback Asset Management — Series A
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Kyowa Kirin — Series A